Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARQT
stocks logo

ARQT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
109.83M
+53.91%
0.076
-184.12%
98.23M
+49.18%
0.033
-116.67%
111.38M
+36.65%
0.110
-184.62%
Estimates Revision
The market is revising Upward the revenue expectations for Arcutis Biotherapeutics, Inc. (ARQT) for FY2025, with the revenue forecasts being adjusted by 7.02% over the past three months. During the same period, the stock price has changed by 81.69%.
Revenue Estimates for FY2025
Revise Upward
up Image
+7.02%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-65.84%
In Past 3 Month
Stock Price
Go Up
up Image
+81.69%
In Past 3 Month
Wall Street analysts forecast ARQT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 28.67 USD with a low forecast of 21.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ARQT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 28.67 USD with a low forecast of 21.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.160
sliders
Low
21.00
Averages
28.67
High
32.00
Current: 31.160
sliders
Low
21.00
Averages
28.67
High
32.00
Mizuho
Uy Ear
Outperform
maintain
$32 -> $37
2025-11-28
Reason
Mizuho
Uy Ear
Price Target
$32 -> $37
2025-11-28
maintain
Outperform
Reason
Mizuho analyst Uy Ear raised the firm's price target on Arcutis Biotherapeutics to $37 from $32 and keeps an Outperform rating on the shares. With one month remaining in Q4, Zoryve prescription trends have been stronger than expected, the analyst tells investors in a research note. The firm upped its Q4 sales estimate to $113M, above the $110M consensus, and 2026 estimate to $470M, above the $467M consensus. Mizuho also has greater confidence in the potential of Zoryve to convert the steroidal market.
Goldman Sachs
Richard Law
Neutral
maintain
$19 -> $29
2025-10-30
Reason
Goldman Sachs
Richard Law
Price Target
$19 -> $29
2025-10-30
maintain
Neutral
Reason
Goldman Sachs analyst Richard Law raised the firm's price target on Arcutis Biotherapeutics to $29 from $19 and keeps a Neutral rating on the shares. Arcutis announced Q3 results and hosted an Investor Day to present more information on its three growth pillars that could potentially drive Zoryve's peak sales to $2.6B-$3.5B per annum, the analyst tells investors in a research note. Goldman's updated model assumes sustained growth without the need for future capital raises.
Mizuho
NULL -> Outperform
maintain
$26 -> $32
2025-10-29
Reason
Mizuho
Price Target
$26 -> $32
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Arcutis Biotherapeutics to $32 from $26 and keeps an Outperform rating on the shares.
H.C. Wainwright
Douglas Tsao
Buy
maintain
$22 -> $30
2025-10-29
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$22 -> $30
2025-10-29
maintain
Buy
Reason
H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Arcutis Biotherapeutics to $30 from $22 and keeps a Buy rating on the shares. The company reported strong Q3 results as Zoryve again beat expectations, the analyst tells investors in a research note.
H.C. Wainwright
Buy
maintain
$19 -> $22
2025-08-07
Reason
H.C. Wainwright
Price Target
$19 -> $22
2025-08-07
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Arcutis Biotherapeutics to $22 from $19 and keeps a Buy rating on the shares following the Q2 report.
TD Cowen
Buy
maintain
$20 -> $25
2025-08-07
Reason
TD Cowen
Price Target
$20 -> $25
2025-08-07
maintain
Buy
Reason
TD Cowen raised the firm's price target on Arcutis Biotherapeutics to $25 from $20 and keeps a Buy rating on the shares. The firm notes total product sales beat consensus, with management reporting 19% quarter-to-quarter prescription growth, and GTN remains stable in the 50% range. Near-term growth will be driven by commercial execution and indication expansion. Zoryve life-cycle management and a focused subset of 40-plus possible inflammatory derm indications support mid-term growth, with pipeline and BD fueling long-term gains, TD Cowen adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT.O) is 82.22, compared to its 5-year average forward P/E of -8.77. For a more detailed relative valuation and DCF analysis to assess Arcutis Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.77
Current PE
82.22
Overvalued PE
17.77
Undervalued PE
-35.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.17
Undervalued EV/EBITDA
-46.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
102.10
Current PS
0.00
Overvalued PS
279.71
Undervalued PS
-75.51
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARQT News & Events

Events Timeline

(ET)
2025-11-17
08:16:47
Arcutis Biotherapeutics Reveals FDA Acceptance of Supplemental New Drug Application for ZORYVE
select
2025-11-13 (ET)
2025-11-13
08:17:51
Arcutis Biotherapeutics finishes participant enrollment for Phase 2 INTEGUMENT-INFANT study
select
2025-11-04 (ET)
2025-11-04
08:11:49
Arcutis Biotherapeutics Releases Phase 2 Study Data for ZORYVE
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-29NASDAQ.COM
Mizuho Continues to Endorse Arcutis Biotherapeutics (ARQT) with an Outperform Rating

  • Analyst Recommendation: Mizuho has maintained an "Outperform" rating for Arcutis Biotherapeutics, with a one-year price target average of $31.62/share, indicating a potential upside of 3.16% from its current price of $30.65/share.

  • Projected Revenue and EPS: Arcutis Biotherapeutics is projected to achieve annual revenue of $1,764 million, reflecting a significant increase of 454.84%, while the expected non-GAAP EPS is -3.47.

  • Fund Sentiment: There are 434 funds reporting positions in Arcutis, with a slight increase in ownership over the last quarter, although total shares owned by institutions decreased by 0.71%.

  • Shareholder Activity: Notable shareholders like Jennison Associates and Polar Capital Holdings have adjusted their holdings, with Jennison increasing its shares by 9.34% while Suvretta Capital Management decreased its shares by 10.09%.

[object Object]
Preview
6.0
11-28Benzinga
Mizuho Reaffirms Outperform Rating for Arcutis Biotherapeutics and Increases Price Target to $37

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
9.0
11-21NASDAQ.COM
Reasons Behind the Recent Surge in Arcutis Biotherapeutics Shares This Week

  • Arcutis Market Expansion: Arcutis Biotherapeutics is expanding its market reach with the FDA's acceptance of a supplemental New Drug Application for Zoryve cream, aimed at treating plaque psoriasis in children aged two to five years.

  • Sales Performance: The company's stock has seen a significant increase of 96% in 2025, bolstered by strong third-quarter results and optimistic sales guidance for Zoryve.

  • Zoryve Approvals: Zoryve is already approved for multiple inflammatory dermatoses and has received prior approvals for treating older children, indicating a growing potential market for the product.

  • Investment Considerations: Despite the positive developments for Arcutis, it was not included in a recent list of top stock recommendations by the Motley Fool, which highlights other stocks with potentially higher returns.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT) stock price today?

The current price of ARQT is 31.16 USD — it has increased 4.01 % in the last trading day.

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s business?

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

arrow icon

What is the price predicton of ARQT Stock?

Wall Street analysts forecast ARQT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 28.67 USD with a low forecast of 21.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s revenue for the last quarter?

Arcutis Biotherapeutics Inc revenue for the last quarter amounts to 99.22M USD, increased 121.69 % YoY.

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s earnings per share (EPS) for the last quarter?

Arcutis Biotherapeutics Inc. EPS for the last quarter amounts to 0.06 USD, decreased -118.18 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arcutis Biotherapeutics Inc (ARQT)'s fundamentals?

The market is revising Upward the revenue expectations for Arcutis Biotherapeutics, Inc. (ARQT) for FY2025, with the revenue forecasts being adjusted by 7.02% over the past three months. During the same period, the stock price has changed by 81.69%.
arrow icon

How many employees does Arcutis Biotherapeutics Inc (ARQT). have?

Arcutis Biotherapeutics Inc (ARQT) has 342 emplpoyees as of December 05 2025.

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT) market cap?

Today ARQT has the market capitalization of 3.82B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free